[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567540":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":41,"collaborators":7,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":7,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":50,"maxAge":7,"enrollmentInfo":51,"targetDuration":7,"studyType":54,"phases":7,"briefSummary":55,"conditions":56,"keywords":7,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"The Third Xiangya Hospital of Central South University","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Weihong Jiang","CONTACT","（86）13786113632","jiangweihongdoc@163.com",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"Ye Chen","（86）18674319338","chenye1223@126.com",[19],{"facility":5,"status":20,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"RECRUITING","Changsha","Hunan","410013","China","CN",{"type":27,"coordinates":28},"Point",[29,30],112.97087,28.19874,{"lat":30,"lon":29},[33,36,39,40],{"name":34,"role":11,"phone":35,"phoneExt":7,"email":13},"Weihong Jiang, Doctor","0086-13786113632",{"name":37,"role":11,"phone":38,"phoneExt":7,"email":17},"Ye Chen, Master","0086-18674319338",{"name":34,"role":11,"phone":7,"phoneExt":7,"email":7},{"name":37,"role":11,"phone":7,"phoneExt":7,"email":7},{"type":42,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100567540","correlation-of-blood-serum-renalase-and-microcirculation-obstruction-in-patients-with-acute-myocardial-infarction-after-primary-percutaneous-coronary-intervention-100567540",false,"NCT06669520","Correlation of Blood Serum Renalase and Microcirculation Obstruction in Patients with Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. STEMI symptom onset time \\\u003C 12 hours;\n3. STEMI symptom onset time 12-48 hours with persistent ischemic symptoms, hemodynamic instability, or life-threatening ventricular arrhythmias;\n4. High-risk NSTEMI;\n5. Emergency PCI;\n6. Voluntary informed consent.\n\nExclusion Criteria:\n\n1. Non-obstructive acute myocardial infarction;\n2. Severe chronic kidney disease (defined as estimated glomerular filtration rate \\\u003C 20 mL\u002Fmin per 1.73 m²);\n3. Life expectancy \\\u003C 1 year;\n4. Pregnant or planning to become pregnant;\n5. Emergency PCI failure.","ALL","18 Years",{"count":52,"type":53},200,"ESTIMATED","OBSERVATIONAL","This research will explore the association between blood serum renalase and microcirculation obstruction in patients with acute myocardial infarction (AMI) after primary percutaneous coronary intervention (PCI). The investigators aim to identify potential risk factors for microcirculation obstruction in AMI patients after PPCI.",[57],"Acute Myocardial Infarction","2024-10-30",{"date":60,"type":61},"2024-11-01","ACTUAL",{"date":63,"type":61},"2024-08-01",{"date":65,"type":53},"2025-10-01",{"name":5,"class":6},1]